Combination therapy with oral PUVA and corticosteroid for recalcitrant alopecia areata

Arch Dermatol Res. 2009 Jun;301(5):373-80. doi: 10.1007/s00403-009-0936-8. Epub 2009 Mar 20.

Abstract

Alopecia areata (AA) is regarded as a tissue-specific autoimmune disease for which several therapies have been suggested to modify the immune reaction against HFs, such as contact immunotherapy, psoralen plus ultraviolet A (PUVA), corticosteroids, cyclosporine, minoxidil, and dithranol. However, severe type AA, such as alopecia totalis (AT) and alopecia universalis (AU), often show resistance against these therapies. We applied a combination therapy with oral corticosteroid and oral PUVA for intractable cases of AT and AU. These patients took 20 mg/day corticosteroid and were irradiated with UVA on the whole body 2 h after taking methoxsalen for 1 month. In all patients, the terminal hair on the whole scalp regrew after 2 months. Two patients had a relapse of hair loss 3 months after the termination of the treatment. FACS analysis revealed that the CD4+CD25(high) and CD4+CD25+FOXP3+ Treg population in PBMC was increased after the combination therapy. Furthermore, the number of infiltrating cells decreased and FOXP3+ cells were often found in lesion skin after the combination therapy. Mitogen-induced proliferation tests showed low responses against PHA and Con A after the combination therapy. Taken together, the combination therapy may modify the systemic immune system and increase the number of Treg cells, resulting in improvement of recalcitrant AA.

MeSH terms

  • Administration, Oral
  • Adrenal Cortex Hormones / therapeutic use*
  • Adult
  • Alopecia Areata / drug therapy*
  • Alopecia Areata / immunology
  • Alopecia Areata / pathology
  • Alopecia Areata / physiopathology
  • CD4 Antigens
  • Cell Movement / drug effects
  • Cell Movement / immunology
  • Cell Separation
  • Drug Resistance
  • Female
  • Flow Cytometry
  • Forkhead Transcription Factors
  • Hair / drug effects*
  • Hair / growth & development
  • Hair / pathology
  • Humans
  • Immunosuppression Therapy
  • Interleukin-2 Receptor alpha Subunit
  • Lymphocyte Activation / drug effects
  • Male
  • Middle Aged
  • PUVA Therapy*
  • Skin / drug effects
  • Skin / immunology
  • Skin / pathology
  • T-Lymphocytes, Regulatory / drug effects
  • T-Lymphocytes, Regulatory / immunology
  • T-Lymphocytes, Regulatory / metabolism*
  • T-Lymphocytes, Regulatory / pathology

Substances

  • Adrenal Cortex Hormones
  • CD4 Antigens
  • FOXP3 protein, human
  • Forkhead Transcription Factors
  • Interleukin-2 Receptor alpha Subunit